An IntroductionAll 7 constituents in our American Cannabis MSO Portfolio declined last week by an average of 8.2% and are now down 36.7%, on average, since the transient excitement of April 30th (when the DEA announced that it planned to follow through on the DHS recommendation that cannabis be reclassified from that of a Schedule I drug to a less stringently regulated Schedule III drug).Back in September the Portfolio soared 122% within 3 weeks of the initial re-classification announcement only to retreat by the end of October to below what it had been when the reclassification was initially recommended; and such a decline could be happening again. The 7 stocks are now down 17.8% below where they were, on average, just 7 weeks ago (April 26th).Below are the details of the returns of the stocks in the American Cannabis MSOs Portfolio by constituent, in ascending order, for the week ending June 14th and since the April 30th peak:
Average: down 8.2% w/e June 14th; down 36.7% since April 30thConclusionThe American Cannabis MSOs Portfolio may well have further to decline based on historical data (see here) so the question now is how much further could it drop before stabilizing. Time will tell. Stay tuned.More By This Author:The Latest News On America’s 10 Largest Semiconductor Companies
These 6 Companies Are The Future Of Semiconductor Growth In Europe
Apple Jumps Peers With Upgrades To Its AI-Capable PC Offerings
